Twin Capital Management Inc. Sells 5,541 Shares of Amgen Inc. $AMGN

Twin Capital Management Inc. reduced its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 27.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,780 shares of the medical research company’s stock after selling 5,541 shares during the quarter. Twin Capital Management Inc.’s holdings in Amgen were worth $4,171,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Sequoia Financial Advisors LLC boosted its stake in shares of Amgen by 2.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after buying an additional 3,619 shares during the last quarter. Atlantic Union Bankshares Corp raised its holdings in Amgen by 165.0% during the second quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock worth $2,972,000 after acquiring an additional 6,627 shares in the last quarter. Davis Capital Management bought a new position in Amgen in the third quarter valued at approximately $1,841,000. D.A. Davidson & CO. grew its stake in Amgen by 2.6% in the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after purchasing an additional 6,222 shares in the last quarter. Finally, Global Wealth Management Investment Advisory Inc. raised its stake in shares of Amgen by 56.2% during the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock worth $3,684,000 after purchasing an additional 4,699 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of AMGN stock opened at $384.20 on Friday. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $385.12. The company has a market capitalization of $206.88 billion, a price-to-earnings ratio of 27.00, a PEG ratio of 3.73 and a beta of 0.46. The company has a 50-day simple moving average of $334.45 and a 200 day simple moving average of $311.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.99 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same period last year, the business posted $5.31 earnings per share. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is currently 66.90%.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Guggenheim raised their target price on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research note on Friday. DZ Bank boosted their price objective on shares of Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Daiwa Securities Group lifted their price target on Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Finally, Truist Financial boosted their price target on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $351.65.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

Insiders Place Their Bets

In related news, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This trade represents a 30.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 10,908 shares of company stock worth $3,674,966 in the last 90 days. Company insiders own 0.76% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.